![Ronda Schreiber](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ronda Schreiber worked as a Director at Plus Therapeutics, Inc., a Principal at Selective Genetics, Inc., and a Vice President-Research at Vessix Vascular, Inc. She completed her undergraduate degree at the University of California, Berkeley and her doctorate degree at City University London.
| Companies | Position | End |
|---|---|---|
| PLUS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2010-01-26 |
Selective Genetics, Inc.
 Selective Genetics, Inc. Medical SpecialtiesHealth Technology Develops gene therapeutics and DNA devices for tissue repair and regeneration | Corporate Officer/Principal | - |
Vessix Vascular, Inc.
 Vessix Vascular, Inc. Pharmaceuticals: OtherHealth Technology Develops products to treat artery disease | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 5 |
|---|---|
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selective Genetics, Inc.
Selective Genetics, Inc. Medical SpecialtiesHealth Technology Develops gene therapeutics and DNA devices for tissue repair and regeneration | Health Technology |
Plus Therapeutics, Inc.
 Plus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops radio therapeutics products | Health Technology |
Vessix Vascular, Inc.
Vessix Vascular, Inc. Pharmaceuticals: OtherHealth Technology Develops products to treat artery disease | Health Technology |
City University London
 City University London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select your edition
All financial news and data tailored to specific country editions
